Harvard Bioscience Reports Second Quarter 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Harvard Bioscience Reports Second Quarter 2016 Financial Results

HOLLISTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO ), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and six months ended June 30, 2016.

Revenues for the three and six months ended June 30, 2016 were $26.1 million and $53.1 million, respectively.  Loss per diluted share, as measured under U.S. generally accepted accounting principles (“GAAP”), for the three and six months ended June 30, 2016 was $0.02 and $0.04, respectively, while earnings per diluted share, on a non-GAAP basis, was $0.03 and $0.08, respectively, for the same periods.

Jeffrey Duchemin, President and CEO of Harvard Bioscience, said, “At the half way point of fiscal year 2016, we remain confident in achieving our financial objectives and goals for the year.  Our second quarter results reflect some near term challenges faced in the quarter.  We believe the most challenging time of the year is behind us and our results will benefit from a few tailwinds in the second half of the year.  For one, our former GE spectrophotometer business, which was negatively impacted by GE’s decision to discontinue sales in the second half of 2015, continues to ramp up and will be up side for us for the remaining six months of the year as compared to the same periods in 2015.  We continue to be pleased with our progress as we develop this direct channel since taking over the sales and service of NanoVue and SimpliNano spectrophotometers on January 1, 2016.”

“Overall, we remain steadfast in our commitment to our strategic priorities and the shareholder value we believe it creates.  We are positioned to finish the year strongly through commercial and operational execution.”

Second Quarter Reported Results

  • Revenues for the three months ended June 30, 2016 were $26.1 million, a decrease of approximately $2.7 million, or 9% compared to revenues of $28.8 million for the three months ended June 30, 2015. Excluding currency translation, revenues decreased 9% or $2.5 million. For a reconciliation of changes in revenues, refer to Exhibit 8 below.  
  • Net loss, as measured under U.S. generally accepted accounting principles (“GAAP”), was $0.7 million, or $0.02 per diluted share, for the three months ended June 30, 2016 compared to net income of $0.3 million, or $0.01 per diluted share, for the same quarter in 2015.  
  • Net income, on a non-GAAP basis, was $1.0 million, or $0.03 per diluted share, for the three months ended June 30, 2016, compared to $1.6 million, or $0.05 per diluted share, for the three months ended June 30, 2015. For a reconciliation between GAAP and non-GAAP net income, and between GAAP and non-GAAP diluted earnings per share, refer to Exhibits 5 and 6 below, respectively. Additionally, refer to Exhibit 9 for the non-GAAP consolidated statement of operations. 

Year-to-Date Reported Results

  • Revenues for the six months ended June 30, 2016 were $53.1 million, a decrease of approximately $1.5 million, or 3% compared to revenues of $54.6 million for the six months ended June 30, 2015. Excluding currency translation, revenues decreased 2% or $0.9 million. For a reconciliation of changes in revenues, refer to Exhibit 8 below.       
  • Net loss, as measured under GAAP, was $1.3 million, or $0.04 per diluted share, for the six months ended June 30, 2016 compared to $1.1 million, or $0.03 per diluted share, for the six months ended June 30, 2015.  
  • Net income, on a non-GAAP basis, was $2.6 million, or $0.08 per diluted share, for the six months ended June 30, 2016 compared to $2.3 million, or $0.07 per diluted share, for the same period in 2015. For a reconciliation between GAAP and non-GAAP net income, and between GAAP and non-GAAP diluted earnings per share, refer to Exhibits 5 and 6 below, respectively. Additionally, refer to Exhibit 9 for the non-GAAP consolidated statement of operations.

Financial Guidance

Today we are updating our full-year 2016 financial guidance, as issued on April 29, 2016, to reflect current foreign currency exchange rates, including the impact of Brexit uncertainty on current British pound sterling rates.  We now expect to report revenues of approximately $108 million to $110 million.

On the bottom-line, we now expect to report full-year 2016 GAAP diluted earnings per share of approximately $0.00 to $0.02 and non-GAAP diluted earnings per share of $0.16 to $0.18, or a 23% to 38% increase compared to 2015 non-GAAP diluted earnings per share.

The Company may incur charges, realize gains, or experience other events in 2016 that could cause actual results to vary from this guidance. Refer to Exhibit 7 below for a reconciliation between the GAAP and non-GAAP diluted earnings per share guidance.

Conference Call Details                         Harvard Bioscience will be hosting a conference call and webcast today at 8:30 am ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.

Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4540, or international: 1-847-619-6397, and referencing the conference ID# 43011203.

The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at http://investor.harvardbioscience.com/ and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.

If you are unable to listen to the live conference call, the webcast will be available on the Company's website through August 4, 2016.

To add this meeting to your calendar visit: http://investor.harvardbioscience.com/  and click “remind me”.

Use of Non-GAAP Financial Information

In this press release, we have included non-GAAP financial information including revenues, adjusted operating income, adjusted net income and adjusted earnings per diluted share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures of revenues and income have excluded certain revenues and expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as currency translation, amortization of intangibles related to acquisitions, costs related to acquisition initiatives, forensic investigation costs, severance and restructuring expenses and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our non-GAAP adjusted operating income, non-GAAP adjusted net income and non-GAAP adjusted earnings per diluted share for the three and six months ended June 30, 2016 and 2015 are included as exhibits below in this press release.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com .

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, the impact of acquisitions, or potential acquisitions, the outlook for the life sciences industry, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts.

These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause the Company's actual results to differ materially from those in the forward-looking statements include reductions in customers’ research budgets or government funding; domestic and global economic conditions; economic, political and other risks associated with international revenues and operations; currency exchange rate fluctuations; economic and political conditions generally and those affecting pharmaceutical and biotechnology industries; the seasonal nature of purchasing in Europe; the Company's failure to expand into foreign countries and international markets; the Company’s failure to realize the expected benefits of facility consolidations; the Company's inability to manage its growth; competition from the Company's competitors; material weakness in the Company’s internal control over financial reporting; failure or inadequacy of the Company's information technology structure; impact of difficulties implementing our enterprise resource planning systems; the Company's failure to identify potential acquisition candidates and successfully close such acquisitions with favorable pricing or integrate acquired businesses or technologies; unanticipated costs relating to acquisitions and known and unknown costs arising in connection with the Company's consolidation of business functions and any restructuring initiatives; the Company’s inability to effectively sell spectrophotometer products following the retirement of the GE Healthcare brand; failure of any banking institution in which the Company deposits its funds or the institution's failure to provide services; the Company's substantial debt and its ability to meet the financial covenants contained in its credit facility; the Company's failure to raise or generate capital necessary to implement its acquisition and expansion strategy, expand operation and invest in new products; the failure of the Company's spin-off of Harvard Apparatus Regenerative Technology, Inc. (now known as Biostage, Inc., “Biostage”), to qualify as a transaction that is generally tax-free for U.S. federal income tax purposes; the failure of Biostage to indemnify the Company for any liabilities associated with Biostage’s business; impact of any impairment of the Company's goodwill or intangible assets; the Company's ability to retain key personnel; rising commodity and precious metals costs; the Company's ability to protect its intellectual property and operate without infringing on others' intellectual property; exposure to product and other liability claims; plus factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015 or otherwise described in our other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.

Exhibit 1        
HARVARD BIOSCIENCE, INC.
Condensed Consolidated Balance Sheet Information
(unaudited, in thousands)
         
         
    June 30,   December 31,
      2016       2015  
Assets        
         
  Cash and cash equivalents   $ 3,631     $ 6,744  
  Trade receivables     16,347       17,547  
  Inventories      22,209       22,343  
  Property, plant and equipment     5,641       5,902  
  Goodwill and other intangibles     60,577       62,452  
  Other assets     5,680       5,062  
  Total assets   $ 114,085     $ 120,050  
         
Liabilities and Stockholders' Equity        
         
  Total current liabilities   $ 14,850     $ 19,323  
  Total liabilities     37,422       42,452  
  Stockholders’ equity     76,663       77,598  
  Total liabilities and stockholders’ equity   $ 114,085     $ 120,050  
Exhibit 2                        
HARVARD BIOSCIENCE, INC.  
Consolidated Statements of Operations  
(In thousands, except per share data)  
(unaudited)  
                                       
                  Three Months Ended     Six Months Ended  
                  June 30,     June 30,  
                    2016         2015         2016         2015    
                                       
Revenues   $ 26,136       $ 28,800       $ 53,099       $ 54,563    
Cost of revenues     14,461         16,205         28,479         30,490    
  Gross profit     11,675         12,595         24,620         24,073    
                                       
Sales and marketing expenses     5,086         5,128         10,188         10,327    
General and administrative expenses     5,236         4,922         11,184         9,753    
Research and development expenses     1,502         1,714         2,927         3,462    
Restructuring charges     1         54         12         111    
Amortization of intangible assets     690         678         1,370         1,471    
  Total operating expenses     12,515         12,496         25,681         25,124    
                                       
Operating (loss) income     (840 )       99         (1,061 )       (1,051 )  
                                       
Other income (expense):                        
  Foreign exchange     282         (134 )       273         89    
  Interest expense     (180 )       (215 )       (344 )       (437 )  
  Interest income     -         3         1         4    
  Other expense, net     (29 )       (180 )       (79 )       (796 )  
Other income (expense), net     73         (526 )       (149 )       (1,140 )  
                                       
Loss before income taxes     (767 )       (427 )       (1,210 )       (2,191 )  
Income tax (benefit) expense     (54 )       (776 )       139         (1,139 )  
Net (loss) income   $ (713 )     $ 349       $ (1,349 )     $ (1,052 )  
                                       
(Loss) earnings per share:                        
  Basic (loss) earnings per common share   $ (0.02 )     $ 0.01       $ (0.04 )     $ (0.03 )  
                                       
  Diluted (loss) earnings per common share   $ (0.02 )     $ 0.01       $ (0.04 )     $ (0.03 )  
                                       
Weighted average common shares:                        
  Basic     34,127         33,569         34,070         33,240    
                                       
  Diluted     34,127         35,026         34,070         33,240    
Exhibit 3          
HARVARD BIOSCIENCE, INC.
Condensed Cash Flow Information
(unaudited, in thousands)
           
    Six Months Ended
    June 30,
      2016         2015  
           
Cash flows from operations:          
Net loss   $ (1,349 )     $ (1,052 )
Changes in assets and liabilities     (2,377 )       (2,402 )
Other adjustments to operating cash flows     3,942         2,473  
Net cash provided by (used in) operating activities     216         (981 )
           
Investing activities:          
Acquisitions, net of cash acquired     -         (4,545 )
Other investing activities     (412 )       (1,625 )
Net cash used in investing activities     (412 )       (6,170 )
           
Financing activities:          
Proceeds from issuance of debt     2,000         4,050  
Repayments of debt     (4,625 )       (4,850 )
Other financing activities     (9 )       1,832  
Net cash (used in) provided by financing activities     (2,634 )       1,032  
           
Effect of exchange rate changes on cash     (283 )       (613 )
           
Decrease in cash and cash equivalents   $ (3,113 )     $ (6,732 )
Exhibit 4  
HARVARD BIOSCIENCE, INC.  
Reconciliation of GAAP Operating (Loss) Income to Non-GAAP Adjusted Operating Income  
(unaudited, in thousands)  
                       
  Three Months Ended     Six Months Ended  
  June 30,     June 30,  
    2016         2015         2016         2015    
                       
GAAP operating (loss) income $ (840 )     $ 99       $ (1,061 )     $ (1,051 )  
                       
Adjustments:                      
                       
Amortization of intangible assets   690         678         1,370         1,471    
                       
Inventory valuation step-up charges on acquisition   -         402         -         793    
                       
Forensic investigation costs   498         -         1,663         -    
                       
Severance and restructuring charges   1         437         12         783    
                       
Stock-based compensation expense   899         692         1,653         1,272    
                       
Non-GAAP adjusted operating income $ 1,248       $ 2,308       $ 3,637       $ 3,268    
Exhibit 5                      
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP Net (Loss) Income to Non-GAAP Adjusted Net Income
(unaudited, in thousands)
                       
                       
    Three Months Ended     Six Months Ended
    June 30,     June 30,
      2016         2015         2016         2015  
                       
GAAP net (loss) income $   (713 )   $   349     $   (1,349 )   $   (1,052 )
                       
Adjustments:                      
                       
Amortization of intangible assets     690         678         1,370         1,471  
                       
Inventory valuation step-up charges on acquisition     -         402         -         793  
                       
Forensic investigation costs     498         -         1,663         -  
                       
Severance and restructuring charges     1         437         12         783  
                       
Acquisition costs     -         198         6         781  
                       
Stock-based compensation expense     899         692         1,653         1,272  
                       
Income taxes (A)     (386 )       (1,175 )       (799 )       (1,711 )
                       
Non-GAAP adjusted net income $   989     $   1,581     $   2,556     $   2,337  
                       
(A)  Income taxes includes the tax effect of adjusting for the reconciling items.
 
Exhibit 6                    
HARVARD BIOSCIENCE, INC.
Reconciliation of GAAP Diluted (Loss) Earnings Per Common Share to Non-GAAP Adjusted Diluted Earnings Per Common Share
(unaudited)
                     
  Three Months Ended     Six Months Ended
  June 30,     June 30,
    2016         2015         2016         2015  
                     
GAAP diluted (loss) earnings per common share $ (0.02 )     $ 0.01       $ (0.04 )     $ (0.03 )
                     
Adjustments:                    
                     
Amortization of intangible assets   0.02         0.02         0.04         0.05  
                     
Inventory valuation step-up charges on acquisition   -         0.01         -         0.02  
                     
Forensic investigation costs   0.01         -         0.05         -  
                     
Severance and restructuring charges   -         0.01         -         0.02  
                     
Acquisition costs   -         0.01         -         0.02  
                     
Stock-based compensation expense   0.03         0.02         0.05         0.04  
                     
Income taxes  (A)   (0.01 )       (0.03 )       (0.02 )       (0.05 )
                     
Non-GAAP adjusted diluted earnings per common share $ 0.03       $ 0.05       $ 0.08       $ 0.07  
                     
(A)  Income taxes includes the tax effect of adjusting for the reconciling items.
Exhibit 7          
HARVARD BIOSCIENCE, INC.
Reconciliation of Guidance for 2016 GAAP Diluted Earnings per Common Share to Non-GAAP Adjusted Diluted Earnings per Common Share
(unaudited)
           
       
GAAP diluted earnings per common share (A)   $   0.00 - 0.02      
           
Adjustments:          
           
Amortization of intangible assets       0.08      
           
Forensic investigation costs       0.05      
           
Stock-based compensation expense       0.09      
           
Income taxes (B)       (0.06 )    
           
Non-GAAP adjusted diluted earnings per common share (A)   $   0.16 - 0.18      
           
(A)  This guidance excludes the impact of future acquisitions, acquisition costs or restructuring charges.  
   
(B)  Income taxes includes the tax effect of adjusting for the reconciling items.  
Exhibit 8                                                
HARVARD BIOSCIENCE, INC.
Reconciliation of Changes In Revenues Compared to the Same Period of the Prior Year
(unaudited)
                                                 
    Three Months Ended   For the Year Ended   Three Months Ended   For the Year Ended   Three Months Ended   Six Months Ended
    Jun. 30,   Sept. 30,   Dec. 31,   Dec. 31,   Mar. 31,   Jun. 30,   Sept. 30,   Dec. 31,   Dec. 31,   Mar. 31,   Jun. 30,   Jun. 30,
      2014       2014       2014       2014       2015       2015       2015       2015       2015       2016       2016       2016  
                                                 
Growth     0.7 %     0.0 %     11.0 %     2.4 %     3.8 %     11.5 %     3.9 %     -3.3 %     3.7 %     6.0 %     -8.6 %     -1.7 %
                                                 
Foreign exchange effect     2.6 %     1.2 %     -2.0 %     0.9 %     -4.3 %     -4.7 %     -2.8 %     -3.3 %     -3.7 %     -1.3 %     -0.7 %     -1.0 %
                                                 
Total revenue growth     3.3 %     1.2 %     9.0 %     3.3 %     -0.5 %     6.8 %     1.1 %     -6.6 %     0.0 %     4.7 %     -9.3 %     -2.7 %
Exhibit 9                        
HARVARD BIOSCIENCE, INC.  
Consolidated Statements of Non-GAAP Adjusted Net Income  
(In thousands, except per share data)  
(unaudited)  
                                       
                  Three Months Ended     Six Months Ended  
                  June 30,     June 30,  
                    2016         2015         2016         2015    
                                       
Revenues   $ 26,136       $ 28,800       $ 53,099       $ 54,563    
Cost of revenues     14,445         15,654         28,452         29,527    
  Gross profit     11,691         13,146         24,647         25,036    
                                       
Sales and marketing expenses     4,951         5,000         9,952         10,112    
General and administrative expenses     4,019         4,207         8,180         8,313    
Research and development expenses     1,473         1,631         2,878         3,343    
  Total operating expenses     10,443         10,838         21,010         21,768    
                                       
Operating income     1,248         2,308         3,637         3,268    
                                       
Other income (expense):                        
  Foreign exchange     282         (134 )       273         89    
  Interest expense     (180 )       (215 )       (344 )       (437 )  
  Interest income     -         3         1         4    
  Other (expense) income, net     (29 )       18         (73 )       (15 )  
Other income (expense), net     73         (328 )       (143 )       (359 )  
                                       
Income before income taxes     1,321         1,980         3,494         2,909    
Income tax expense     332         399         938         572    
Net income   $ 989       $ 1,581       $ 2,556       $ 2,337    
                                       
Earnings per share:                        
  Basic earnings per common share   $ 0.03       $ 0.05       $ 0.08       $ 0.07    
                                       
  Diluted earnings per common share   $ 0.03       $ 0.05       $ 0.08       $ 0.07    
                                       
Weighted average common shares:                        
  Basic     34,127         33,569         34,070         33,240    
                                       
  Diluted     34,127         35,026         34,070         33,240    

 

CONTACTS: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999 Fax: 508 429 8478

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 0

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 156

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 395

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 145

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 22

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 149

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Wells Fargo's Insight on Industrial Stocks Amid Elections

Updated Category News Views 231

Wells Fargo's Industrial Sector Election Guide As the US presidential election approaches, Wells Fargo has closely examined the Industrials sector, pinpointing potential winners and those stocks that may face challenges. This analysis is particularly noteworthy given the significant changes in policy that may arise depending on the election outcome. Key Areas of Focus in...

Continue Reading
Woodward Secures Airbus Supplier Role for A350 Actuation System

Updated Category News Views 318

Woodward Partners with Airbus for A350 Spoiler Actuation Woodward, a prominent player in aerospace and energy control solutions, has been selected as a key supplier for Airbus's A350 Spoiler Actuation System. This collaboration marks another significant milestone in their long-standing relationship, demonstrating Woodward’s commitment to providing top-notch technology...

Continue Reading
GreenPower Motor Company Secures Significant Loan for Growth

Updated Category News Views 327

GreenPower Motor Company Announces Successful Loan Closure GreenPower Motor Company Inc. (NASDAQ: GP) has officially completed the third tranche of its secured term loan offering, securing an impressive aggregate principal amount of U.S. $300,000. The company specializes in designing and distributing all-electric, purpose-built, zero-emission vehicles tailored for various...

Continue Reading
Carrier Global's Strategic Moves to Enhance Market Growth

Updated Category News Views 383

Understanding Carrier Global's Transformation Journey Carrier Global Corporation (NYSE: CARR) is a leading entity in the heating, ventilation, and air conditioning (HVAC) industry, known for its ongoing transformation since its spin-off in 2020. This article delves into the company’s strategic maneuvers, financial trajectory, and competitive positioning to inform...

Continue Reading
International School of Permanent Makeup Enhances Education Offerings

Updated Category News Views 252

International School of Permanent Makeup Unveils New Website The International School of Permanent Makeup (ISPMU) has officially launched its redesigned website, providing an updated platform for aspiring beauty professionals to explore advanced certification courses. This move reflects ISPMU's commitment to delivering top-quality education in the permanent makeup field....

Continue Reading